OCT 21, 2020 7:30 AM PDT

New ALS Treatment Extends Life for Several Months

WRITTEN BY: Annie Lennon

Currently, there are only two approved medications to treat Lou Gehrig's disease (also known as ALS), a condition popularized by the Ice Bucket Challenge. With neither of these medications being particularly effective, a two-drug combination developed by two college students from Brown University seven years ago has been found to allow patients to live several months longer.  

Known as AMX0035, the drug combination consists of an existing supplement and a medication for a pediatric urea disorder. 

For the study, researchers recruited 137 patients who had developed symptoms of ALS at least 18 months before the trial, were affected in at least three parts of the body, and had signs of the disease progressing rapidly. Most were already taking one or both of the approved ALS medications. 

All in all, it was found that the new drug combination managed to slow the progression of ALS paralysis by around 25% more than the placebo. Moreover, the researchers behind the study found that those receiving the placebo declined in 18 weeks to a level that patients receiving the treatment reached only after 24 weeks. 

One weakness of the study, however, is that it was only conducted for 24 weeks. Thereafter, those given the placebo were given the option to take the therapy for up to 30 months. As such, the researchers do not have full results for patients who only received the placebo for 30 months to compare with those receiving the treatment from Day 1. 

Nevertheless, the study reported that people who received AMX0035 during the trial and afterward lived an average of 6.5 months longer than those originally o the placebo- or 25 months compared to 18.5 months. 

While promising results, Dr. Walter Koroshetz, director of the National Institute of Neurological Disorders and Stroke, who wasn't involved in the trial, said that it wasn't clear how much the treatment benefited those who received it only after the 24-week trial. 

"It could mean that the drug is really effective and people who got the drug late really would have been dead at 12 months instead of 18," he said. "Or, the other way of thinking about it is that the drug is not effective unless you get it early. There's no clue here to which one of those is true."

 

SOurces: New York TimesUS News

 

About the Author
  • Science writer with keen interests in technology and behavioral biology. Her current focus is on the interplay between these fields to create meaningful interactions, applications and environments.
You May Also Like
SEP 13, 2020
Drug Discovery & Development
Scientists Find Way to Reduce Inflammation from Vaccines
SEP 13, 2020
Scientists Find Way to Reduce Inflammation from Vaccines
Researchers from the University of Chicago have found a new way to reduce vaccine-related inflammation from adjuvants, a ...
SEP 20, 2020
Cell & Molecular Biology
Revealing the Structure of Hallucinogens Bound to Their Receptor
SEP 20, 2020
Revealing the Structure of Hallucinogens Bound to Their Receptor
Recent studies have demonstrated that hallucinogenic drugs like LSD, psilocybin, and mescaline have therapeutic potentia ...
OCT 12, 2020
Cancer
Targeting Energy Production in Cells to Fight Leukemia
OCT 12, 2020
Targeting Energy Production in Cells to Fight Leukemia
Much like how a car needs gasoline to run, cells also need a fuel source. Most human cells in the body use oxidative pho ...
NOV 11, 2020
Health & Medicine
A smart path for novel biologics
NOV 11, 2020
A smart path for novel biologics
Introduction  Cell culture is at the heart of the production process for many biopharmaceuticals, but finding the o ...
OCT 10, 2020
Drug Discovery & Development
Fishnet of Nanoparticles Traps Drug Molecules
OCT 10, 2020
Fishnet of Nanoparticles Traps Drug Molecules
‘Fishnet’ Nanoparticles Traps Drug Molecules A team at Northwestern University have casted a net of nanopart ...
NOV 15, 2020
Drug Discovery & Development
Antidepressant May Prevent Worsening of COVID-19 Infections
NOV 15, 2020
Antidepressant May Prevent Worsening of COVID-19 Infections
  Researchers from the Washington University School of Medicine in St. Louis have found that fluvoxamine, a common ...
Loading Comments...